Vatner D E, Knight D R, Homcy C J, Vatner S F, Young M A
Circ Res. 1986 Oct;59(4):463-73. doi: 10.1161/01.res.59.4.463.
Whether large coronary artery dilation induced by beta-adrenergic stimulation is mediated by beta 1- or beta 2-adrenergic receptors remains controversial. This problem is particularly difficult to address in vivo due to the concomitant increase in coronary blood flow with beta-adrenergic stimulation, which by itself can dilate large coronary arteries. To reconcile this problem, 5 calves were instrumented with intraaortic and intracoronary (i.c.) catheters, ultrasonic diameter transducers, Doppler flow transducers, and hydraulic occluders on the left circumflex coronary artery. Two to six weeks following surgery, beta-adrenergic agonists were administered i.c. to avoid complicating systemic effects. Isoproterenol (0.0025 micrograms/kg, a beta 1 + beta 2-adrenergic agonist) increased coronary diameter (7.1 +/- 0.8% from 5.80 +/- 0.58 mm) (p less than 0.01). Similar increases (p less than 0.01) in coronary diameter occurred with prenalterol (0.4 micrograms/kg, beta 1-adrenergic agonist) (9.5 +/- 1.4%) and pirbuterol (0.25 micrograms/kg, beta 2-adrenergic agonist) (8.1 +/- 1.2%). When coronary blood flow was prevented from rising with the hydraulic constrictor, increases in coronary diameter to all three beta-adrenergic agonists were not attenuated. Large coronary artery dilation with prenalterol and pirbuterol was abolished with beta 1- and beta 2-adrenergic receptor blockade, respectively, while neither beta 1- nor beta 2-adrenergic blockade alone abolished the large coronary artery dilation with isoproterenol. To identify the predominant subtype of beta-adrenergic receptor, competitive inhibition curves utilizing 125I-cyanopindolol (125I-CYP) as the radiolabel versus isoproterenol, epinephrine, and norepinephrine were generated in membrane preparations from calf heart (predominant beta 1), calf lung (predominant beta 2) and calf coronary artery. The coronary artery membrane preparations demonstrated an intermediate pattern. Competition curves with selective beta 1- and beta 2-adrenergic receptor agonists and antagonists again demonstrated a pattern for coronary artery intermediate to that of heart and lung, further confirming the presence of both beta-adrenergic receptor subtypes in large coronary arteries, with a ratio of beta 1: beta 2 of 1.5-2.0:1.0. Thus, large coronary arteries of the calf contain both beta 1- and beta 2-adrenergic receptors identified utilizing ligand binding techniques, and stimulation of both receptor subtypes in the intact conscious animal results in large coronary artery dilation, independent of blood-flow-mediated vasodilation.
β-肾上腺素能刺激引起的大冠状动脉扩张是由β1-还是β2-肾上腺素能受体介导的,目前仍存在争议。由于β-肾上腺素能刺激会伴随冠状动脉血流量增加,而血流量增加本身就可使大冠状动脉扩张,所以这个问题在体内尤其难以解决。为了协调这一问题,给5头小牛植入了主动脉内和冠状动脉内(i.c.)导管、超声直径换能器、多普勒血流换能器以及左旋冠状动脉上的液压闭塞器。术后2至6周,经冠状动脉内给药β-肾上腺素能激动剂以避免复杂的全身效应。异丙肾上腺素(0.0025微克/千克,一种β1 + β2-肾上腺素能激动剂)使冠状动脉直径增加(从5.80±0.58毫米增加7.1±0.8%)(p<0.01)。普瑞特罗(0.4微克/千克,β1-肾上腺素能激动剂)(9.5±1.4%)和吡布特罗(0.25微克/千克,β2-肾上腺素能激动剂)(8.1±1.2%)也使冠状动脉直径出现类似增加(p<0.01)。当用液压收缩器阻止冠状动脉血流量增加时,对所有三种β-肾上腺素能激动剂的冠状动脉直径增加并未减弱。普瑞特罗和吡布特罗引起的大冠状动脉扩张分别被β1-和β2-肾上腺素能受体阻断所消除,而单独的β1-或β2-肾上腺素能阻断均未消除异丙肾上腺素引起的大冠状动脉扩张。为了确定β-肾上腺素能受体的主要亚型,利用125I-氰基吲哚洛尔(125I-CYP)作为放射性标记物,分别与异丙肾上腺素、肾上腺素和去甲肾上腺素在小牛心脏(主要为β1)、小牛肺(主要为β2)和小牛冠状动脉的膜制剂中生成竞争抑制曲线。冠状动脉膜制剂呈现出中间模式。用选择性β1-和β2-肾上腺素能受体激动剂及拮抗剂得到的竞争曲线再次显示出冠状动脉的模式介于心脏和肺之间,进一步证实大冠状动脉中存在两种β-肾上腺素能受体亚型,β1:β2的比例为1.5 - 2.0:1.0。因此,利用配体结合技术鉴定出小牛的大冠状动脉中同时含有β1-和β2-肾上腺素能受体,并且在完整清醒动物中刺激这两种受体亚型都会导致大冠状动脉扩张,这与血流介导的血管舒张无关。